<DOC>
	<DOCNO>NCT02504320</DOCNO>
	<brief_summary>This study assess relative bioavailability , safety tolerability follow administration 80 mg single oral dos 4 febuxostat extend release ( XR ) formulation .</brief_summary>
	<brief_title>Phase 1 , Febuxostat XR Relative Bioavailability Study</brief_title>
	<detailed_description>The drug test study febuxostat XR . Four different formulation febuxostat XR test see drug move body . This study look safety side effect people take febuxostat XR . This cross-over study enroll approximately 78 patient . Participants randomly assign 1of 4 sequence determine order 4 treatment receive : - Febuxostat XR 80 mg capsule Formulation 1 - Febuxostat XR 80 mg capsule Formulation 2 - Febuxostat XR 80 mg capsule Formulation 3 - Febuxostat XR 80 mg capsule Formulation 4 Participants take 1 dose Day 1 washout period period . This single-center trial conduct United States . The overall time participate study 80 day . Participants make multiple visit clinic include period confinement , contact telephone 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure include request participant fast laboratory evaluation . 3 . Is healthy male female age 18 55 year , inclusive , time informed consent first study medication dose . 4 . Weighs least 50.0 kg body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive Screening . 5 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose . 6 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing informed consent , 7 . Is willing refrain strenuous exercise Day 1 Period 1 Study Exit ( Day 3 Period 4 ) . 8 . Has estimate glomerular filtration rate ( eGFR ) â‰¥90 mL/min Screening Checkin ( Day 1 Period 1 ) . 1 . Has receive investigational compound within 30 day prior first dose study medication . 2 . Has receive febuxostat previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study . 4 . Has uncontrolled , clinically significant ( CS ) disease abnormality , may impact ability participant participate potentially confound study result . 5 . Has know hypersensitivity component formulation XO inhibitor , xanthine compound , caffeine , component formulation febuxostat capsule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>